Research programme: neurodegenerative disease therapeutics - Vybion

Drug Profile

Research programme: neurodegenerative disease therapeutics - Vybion

Alternative Names: INT 41; rAAV6-INT41

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vybion
  • Class Antibodies; Gene therapies; Recombinant proteins
  • Mechanism of Action HD protein inhibitors; Protein folding modulators; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Huntington's disease
  • Research Alzheimer's disease; Spinocerebellar degeneration

Most Recent Events

  • 03 Apr 2018 Vybion has patent protection for INT 41 in USA
  • 03 Apr 2018 Vybion has patents pending for INT 41 in Europe and Asia
  • 03 Apr 2018 Pharmacodynamics data from a Preclinical study in Neurodegenerative diseases released by Vybion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top